AnaptysBio

AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO, Sept.  11, 2020  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present at the 2020 Cantor Global Virtual Healthcare Conference on Thursday, September 17, 2020 at 12:00 p.m. ET. The conference will be conducted virtually, and the presentation will be available via  https://www.webcaster4.com/Webcast/Page/2495/37348

AnaptysBio to Present at the 2020 Cantor Global Virtual Healthcare Conference

DENVER--(BUSINESS WIRE)--Shuman, Glenn & Stecker Investigates AnaptysBio, Inc.

Shuman Glenn & Stecker Investigates AnaptysBio, Inc.

SAN DIEGO, Aug.  10, 2020  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today reported operating results for the second quarter ended June 30, 2020 and provided pipeline updates.

AnaptysBio Announces Second Quarter 2020 Financial Results and Provides Pipeline Updates

SAN DIEGO, Aug.  05, 2020  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present at the 2020 Wedbush PacGrow Healthcare Conference on Tuesday, August 11, 2020 at 2:55 p.m. ET. The conference will be conducted virtually, and the presentation will be available via https://wsw.com/webcast/wedbush36/anab/2181318.

AnaptysBio to Present at The 2020 Wedbush PacGrow Healthcare Conference

Dermatology Physician-Scientist To Lead Wholly-Owned Pipeline Advancement Dermatology Physician-Scientist To Lead Wholly-Owned Pipeline Advancement

AnaptysBio Appoints Dr. Paul F. Lizzul As Chief Medical Officer

Appoints Dennis Mulroy as Chief Financial Officer and Eric Loumeau as Chief Operating Officer Appoints Dennis Mulroy as Chief Financial Officer and Eric Loumeau as Chief Operating Officer

AnaptysBio Expands Executive Leadership Team

SAN DIEGO, July  08, 2020  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for imsidolimab, the company’s proprietary anti-interleukin-36 receptor (IL-36R) antibody, for the treatment of patients with GPP. 

AnaptysBio Announces Orphan Drug Designation of Imsidolimab For Treatment of Generalized Pustular Psoriasis

AnaptysBio, Inc. (ANAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

AnaptysBio, Inc. (ANAB) Upgraded to Buy: What Does It Mean for the Stock?

Is  (ANAB) Outperforming Other Medical Stocks This Year?

Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?

The beaten-up biopharma provided an update that revved up interest in its pipeline.

Here's Why AnaptysBio Rose 22.1% in May

NEW YORK, May 19, 2020 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AnaptysBio, Inc. ("Anaptys" or the "Company") (NASDAQ:ANAB) of the May 26, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that...

ANAPTYSBIO DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In AnaptysBio, Inc. To Contact The Firm

NEW YORK, May 15, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AnaptysBio, Inc. (NASDAQ: ANAB) between October 10, 2017 and November 7, 2019, inclusive (the "Class Period"), of the important May 26, 2020 lead plaintiff...

ANAPTYSBIO LOSS NOTICE: ROSEN, A LEADING AND TOP RANKED LAW FIRM, Reminds AnaptysBio, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - ANAB

As of late, it has definitely been a great time to be an investor AnaptysBio

Will AnaptysBio Continue to Surge Higher?

AnaptysBio (ANAB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Is AnaptysBio (ANAB) Stock a Solid Choice Right Now?

Exelixis

Key clinical trial results this quarter will determine the better buy.

Better Buy: AnaptysBio vs. Exelixis

This antibody drug developer can be had for fire-sale prices.

Is AnaptysBio Stock a Buy?

All You Need to Know About AnaptysBio, Inc. (ANAB) Rating Upgrade to Buy

bluebird bio

These three biopharma stocks all ended in positive territory Friday after a week of double-digit declines.

Why AnaptysBio, bluebird bio, and Exelixis Shares Rebounded Last Friday

Editas Medicine

Worries about a coronavirus impact don't make sense.

Why Biotech Stocks AnaptysBio, bluebird bio, and Editas Medicine Are Sinking Today

Co-Diagnostics

Novavax

A pair of black swans crushed these three healthcare stocks today.

Why AnaptysBio, Co-Diagnostics, and Novavax Are Getting Crushed Today

After a rough 2019, investors are excited about the biotech's prospects in the year ahead.

Here's Why Shares of AnaptysBio Jumped Today

TuanChe Limited

Falling knives are companies whose share prices have declined more than 59% over the past 12 months.

Analysts See These 2 Falling Knives Rebounding Within a Year

AnaptysBio Is Due For A Bounce As It Trades Significantly Below Its Net Cash Per Share

AnaptysBio has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

AnaptysBio Enters Oversold Territory

AnaptysBio (ANAB) earnings for the antibody development company's third quarter of 2019 have ANAB stock taking a dive on Friday.

News for AnaptysBio Stock (ANAB)